Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 15:16:e02.
doi: 10.15420/icr.2020.14. eCollection 2020 Apr.

Balloon Pulmonary Angioplasty: State of the Art

Affiliations
Review

Balloon Pulmonary Angioplasty: State of the Art

John G Coghlan et al. Interv Cardiol. .

Abstract

Balloon pulmonary angioplasty (BPA) is a novel technique for the treatment of chronic thromboembolic pulmonary hypertension. While cardiologists need no introduction to the concept of balloon angioplasty, BPA has its own particular challenges. This article aims to provide the reader with an overview of BPA, starting with an introduction to chronic thromboembolic disease (CTED), the standard management of chronic thromboembolic pulmonary hypertension (CTEPH), technical challenges faced when performing BPA and the evidence base supporting its use. The second part of the article will focus on the future of BPA, in particular the areas where research is required to establish an evidence base to justify the role of BPA in CTEPH and CTED treatment.

Keywords: Thromboembolic; angioplasty; complications; endarterectomy; pulmonary; riociguat; thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Disclosure: JC performs balloon pulmonary angioplasty at Royal Papworth Hospital. Unrelated to the current work he receives grants from Johnson & Johnson and Merck. He undertakes consultancy work and has received honoraria from Johnson & Johnson, GSK, Bayer and Endotronix. AR performs balloon pulmonary angioplasty at Royal Papworth Hospital. Unrelated to the current work he receives grants from Johnson & Johnson, Novartis, Medtronic and Abbott. He undertakes consultancy work and has received honoraria from Johnson & Johnson, SoniVie and Endotronix. SH performs balloon pulmonary angioplasty at Royal Papworth Hospital. Unrelated to the current work he has received research grants from AstraZeneca and Abbott Vascular. He undertakes consultancy work and has received honoraria from AstraZeneca, Bayer, Abbott Vascular and Boston Scientific.

Figures

Figure 1:
Figure 1:. Multiple Lesion Types on Pulmonary Angiogram
Figure 2:
Figure 2:. Occlusive Web Disease
Figure 3:
Figure 3:. Complex Web Disease
Figure 4:
Figure 4:. Wire Exit
Figure 5:
Figure 5:. CT Showing Pulmonary Haemorrhage

Similar articles

Cited by

References

    1. D’Agostino C, Zonzin P, Enea I et al. ANMCO Position paper: long-term follow-up of patients with pulmonary thromboembolism. Eur Heart J. 2017;19((Suppl D)):D309–32. doi: 10.1093/eurheartj/sux030. - DOI - PMC - PubMed
    1. Stevens H, Fang W, Clements W et al. Risk stratification of acute pulmonary embolism and determining the effect on chronic cardiopulmonary complications: the REACH Study. TH Open. 2020;4:e45–50. doi: 10.1055/s-0040-1708558. - DOI - PMC - PubMed
    1. Lang IM, Dorfmüller P, Vonk Noordegraaf A. The pathobiology of chronic thromboembolic pulmonary hypertension. Ann Am Thorac Soc. 2016;13((Suppl 3)):S215–21. doi: 10.1513/AnnalsATS.201509-620AS. - DOI - PubMed
    1. Kim NH, Delcroix M, Jais X et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1801915. doi: 10.1183/13993003.01915-2018. - DOI - PMC - PubMed
    1. Konstantinides SV, Vicaut E, Danays T et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol. 2017;69:1536–44. doi: 10.1016/j.jacc.2016.12.039. - DOI - PubMed

LinkOut - more resources